

Plasma amyloid- β is associated with suicidal ideation in older adults: a 15-year follow-up study

Ismael Conejero, Isabelle Jaussent, Jorge Lopez Castroman, Philippe Courtet, Sylvaine Artero

▶ To cite this version:

Ismael Conejero, Isabelle Jaussent, Jorge Lopez Castroman, Philippe Courtet, Sylvaine Artero. Plasma amyloid- β is associated with suicidal ideation in older adults: a 15-year follow-up study. Journal of Neurology, Neurosurgery and Psychiatry, In press, 95 (12), pp.1217-1219. 10.1136/jnnp-2024-333667. hal-04669310

HAL Id: hal-04669310 https://hal.science/hal-04669310v1

Submitted on 8 Aug 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Plasma amyloid-β is associated with suicidal ideation in older adults: a 15-year follow-up study

INTRODUCTION

Suicide rates in older adults surpass those of other age groups, 1 making suicide a major societal problem in this population. Suicidal ideation (SI) and attempts may be related to increased amyloid burden in non-demented individuals, in addition to psychosocial stress factors. While traditionally associated with Alzheimer's disease, amyloid deposits were recently identified in the frontal and occipital cortex of suicide victims.2 They have also been reported to be more frequent in cases of depression,³ although recent contradictory results show reduced AB deposition in depressed older adults compared with cognitively normal non-depressed individuals.4 Reflecting the amyloid load in brain, lower Aβ42/Aβ40 ratio in plasma was associated with depression and with its severity in cognitively normal older adults against healthy controls, after controlling for cognitive performances in a prospective study.⁵ In turn, depressive symptoms may contribute to the emergence of SI and increased suicide risk. A better insight into the role of amyloid-Aß peptides on SI may help clinicians to prevent suicidal behaviour. We hypothesise that plasma AB peptide alterations are associated with the incidence of SI in non-demented older adults.

We used data from the prospective Enquête de Santé Psychologique – Risques, Incidence et Traitement (ESPRIT) cohort to examine the association between plasma $A\beta42$ and $A\beta40$ concentrations, and $A\beta42$ / $A\beta40$ ratio, and the incidence of SI over a 15-year follow-up period in older adults. The possible role of late-life depression (LLD) in this association was studied. We also explored the association between plasma $A\beta$ peptide concentration and the incidence of LLD over time.

METHODS

Data were obtained from the longitudinal ESPRIT study of neuropsychiatric disorders in community-dwelling French older adults aged 65 years and older, part of the 3C multicentre study. Standardised interviews were administrated at baseline and at years 2, 4, 8, 10, 12 and 15 of the follow-up. From the 2268 participants recruited, 310 subjects were randomly selected for plasma A β concentration measurement at baseline and were free of dementia. After excluding participants diagnosed with SI at baseline and those without follow-up visits, we analysed the association between plasma A β and the incidence of SI in the 223 remaining

participants. The association between baseline plasma AB and the incidence of LLD was examined in 235 individuals, excluding those with a history of depression and without follow-up visits (online supplemental figure 1). The presence of passive or active SI in the last month was assessed at baseline and at each follow-up visit using the MINI-international Neuropsychiatry Interview (Mini 5.00), based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-4) criteria. LLD was recorded on a positive response to (1) acute major depressive episode (MINI); (2) Centre for Epidemiologic Studies-Depression Scale score ≥16 and/or (3) antidepressant intake at each visit. Detailed procedures are provided in online supplemental material.

RESULTS

After a median follow-up of 9.7 years, 42 (18.8%) of the 223 participants reported SI. They showed more frequent LLD and were more frequently treated with selective serotonin reuptake inhibitors (SSRI) than individuals reporting no SI. Other baseline clinical characteristics were not statistically different between groups (online supplemental table 1). The baseline $A\beta42/A\beta40$ ratio, categorised into tertiles, was associated with a higher risk of SI, particularly for individuals in the




Figure 1 Incidence of suicidal ideation according to plasma A β 42/A β 40 ratio levels at baseline.



middle tertile. This association remained significant even after adjustment for LLD (model 2: HR 2.83 (95% CI 1.24 to 6.45), p=0.03), and in sensitivity analyses after excluding individuals taking SSRI or cases of incident dementia (figure 1, online supplemental tables 2–4). The A β 42/A β 40 ratio considered as continuous was not associated with SI incidence. Likewise, no significant associations were found between A β 42 or A β 40 considered separately and the incidence of SI.

Among the 235 non-depressed participants at baseline, 42 (17.9%) reported an LLD over the follow-up period. No association was observed between A β 42, A β 40 or the A β 42/A β 40 ratio at baseline, and the incidence of LLD (online supplemental table 5).

DISCUSSION

In this long-term cohort of older adults, we highlighted an association between plasma Aβ42/Aβ40 ratio and subsequent SI over a 15-year period, independently of dementia and LLD. This relationship was not linear, as the individuals in the middle tertile were more likely to report SI compared with those in the lower tertile. Our results may have arisen from the selection of cognitively normal participants, less likely to show severe neurodegeneration compared with demented individuals. Non-linear association patterns may account for the absence of relationship between the A\u00e342/A\u00e340 ratio when considered as continuous and SI.

We did not find any association between AB42 and AB40 considered separately and SI, suggesting that A\(\beta\)42/A\(\beta\)40 ratio may be a more sensitive marker of amyloid dynamics in plasma as reported in a prior study.5 Furthermore, the absence of relationship between plasma AB concentrations and incident LLD over the 15-year follow-up may potentially result in the restricted sample size as we focused on incident LLD and excluded individuals showing depression with enlarged definition at baseline. The link between depression and AB remains controversial, as decreased brain amyloid deposition, was recently reported in depressed older

A limitation of our study is that we performed a single measurement of Aβ. However, possible confounding factors were taken into account in the analysis, including SSRI intake, the educational level, living alone or blood creatinine level at baseline. The income level was not included in the model due to its collinearity with the educational level nor the

diagnosis of mild cognitive impairment. Nonetheless, MMSE scores were not associated with SI.

While we showed a strong relationship between amyloid-A β and SI, the association may have been minimised as we excluded institutionalised people at baseline, who are more likely to report incident SI, and suicide deaths following the surge of SI were not recorded. Future studies should confirm the results using more sensitive measures of peripheral A β and also in the CSF.

CONCLUSION

This study highlights an association between $A\beta42/A\beta40$ ratio in plasma and the occurrence of SI in late life, independently of depression and dementia. These findings, supporting possible agerelated biological pathways underlying suicide, could be of interest for early detection of suicidal risk in older adults as this plasmatic marker is easily accessible.

Ismael Conejero ⁽¹⁾, ^{1,2,3,4} Isabelle Jaussent, ⁵
Jorge Lopez Castroman, ^{6,7} Philippe Courtet, ^{2,8}
Sylvaine Artero²

¹Department of Psychiatry, CHU de Nîmes, University of Montpellier, Nimes, France

²Institute of Functional Genomics (IGF), University of Montpellier, CNRS, INSERM, Montpellier, France ³Department of Psychiatry, Fundación Jiménez Díaz University Hospital, Madrid, Spain

⁴Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Madrid, Spain

⁵Institute for Neurosciences of Montpellier INM, University of Montpellier, INSERM, Montpellier, France ⁶Centro de Investigación Biomédica en Red de Salud Mental, Madrid, Spain

⁷Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain ⁸Department of Emergency Psychiatry & Acute Care, CHU Montpellier, University of Montpellier, Montpellier, France

Correspondence to Dr Ismael Conejero; ismael. conejero@gmail.com Dr Sylvaine Artero; sylvaine. artero@inserm.fr

Acknowledgements We thank Sarah Kabani for proofreading the manuscript. The results were prior presented at the international congress 'Journées Neurosciences Psychiatrie Neurologie' (Paris, France).

Contributors IC designed the study and wrote the manuscript. IJ designed the study and made the statistical analysis and revised the manuscript. JLC drafted and substantially revised the manuscript. PC supervised the study, drafted and revised the manuscript. SA supervised the study, drafted and revised the manuscript. PC and SA contributed equally to this paper. All the authors approved the content of the work.

Funding The ESPRIT project is financed by Novartis, Sanofi and the Fondation pour la recherche médicale.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by the Ethics Committee of the University Hospital of Kremlin-Bicêtre (Paris, France) (Project no 99-28). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.



OPEN ACCES

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

► Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/jnnp-2024-333667).

PC and SA contributed equally.



To cite Conejero I, Jaussent I, Lopez Castroman J, et al . J Neurol Neurosurg Psychiatry Epub ahead of print: [please include Day Month Year]. doi:10.1136/jnnp-2024-333667

Received 21 February 2024 Accepted 28 June 2024

J Neurol Neurosurg Psychiatry 2024;**0**:1–3. doi:10.1136/jnnp-2024-333667

ORCID iD

Ismael Conejero http://orcid.org/0000-0002-9142-1278

REFERENCES

1 Naghavi M, Global Burden of Disease Self-Harm Collaborators. Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the global burden of disease study 2016. BMJ 2019;364:194.

- Stępień T, Heitzman J, Wierzba-Bobrowicz T, et al. Neuropathological changes in the brains of suicide killers. Biomolecules 2021;11:1674.
- 3 Donovan NJ, Locascio JJ, Marshall GA, et al.
 Longitudinal association of amyloid beta and anxious-
- depressive symptoms in cognitively normal older adults. *Am J Psychiatry* 2018;175:530–7.
- 4 Mackin RS, Insel PS, Landau S, *et al*. Late-life depression is associated with reduced cortical amyloid burden: findings from the alzheimer's disease neuroimaging
- initiative depression project. *Biol Psychiatry* 2021;89:757–65.
- 5 Pomara N, Bruno D, Plaska CR, et al. Plasma amyloid-B dynamics in late-life major depression: a longitudinal study. *Transl Psychiatry* 2022;12:301.